



NDA 12-093/S-044

Wyeth-Ayerst
Attention: Ms. Mary Alice Dankulich
150-B3 North Radnor Chester Road
St. Davids, PA 19087

26 SEP 2001

Dear Ms. Dankulich:

Please refer to your supplemental new drug application dated August 23, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Isordil Titradoso (isosorbide dinitrate) 5, 10, 20, 30 and 40 mg Tablets.

We acknowledge receipt of your submission dated August 9, 2001 that constituted a complete response to our March 23, 2001 approvable letter.

This supplemental new drug application provides for final printed labeling revised as follows:

1. Under PRECAUTIONS, a Geriatric Use subsection has been added that reads as follows:

Clinical studies of Isordil (isosorbide dinitrate) Titradoso did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

2. A "Rx Only" statement has been added above the DESCRIPTION section.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert included in your submission of August 9, 2001). Accordingly, the supplemental application is approved effective on the date of this letter.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

NDA 12-093/S-044

Page 2

If you have any questions, please contact:

Mr. Edward Fromm
Regulatory Health Project Manager
(301) 594-5313

Sincerely,

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research